The Efficacy of Teneligliptin with Metformin in Drug-Naïve Type 2 Subjects

Aim: To assess the efficacy of Teneligliptin with metformin in drug naïve type 2 subjects.

Objective: To assess the efficacy of Teneligliptin with metformin in drug naïve type 2 subjects. Primary outcome observe change in HbA1c, FBS and PPBS from baseline to 48 weeks. Secondary outcome is to note the change in BMI and drug safety.

Method: A retrospective analysis of data from December 2016 till December 2017 was carried out at 4 centers of a chain of Diacare-Diabetes care and Hormone Clinic. The inclusion criteria included newly detected type 2 subjects aged 50.0 +_ 7.0 years, who were Drug naïve with mean HbA1c 8.0% (7%-9%), mean Fasting value 144 mg/dl (+/- 18mg/dl) and mean post meal value 220mg/dl (+/-18mg/dl).

All vital parameters with anthropometric data was analyzed, tabulated and reviewed

Result: N=450 subjects. Reduction in HbA1c after 12 weeks was 1.2% from base line and after 24 weeks it was 1.6% and 1.0% at the end of 48 weeks. 66% of subjects were seen with HbA1c <7% at 24^th week. To the rest in whom target was not achieved till 24^th weeks, an interventation was added in the form of OHA along with physical exercise and diet.

Drop in BMI at 12 weeks was 0.6 kg/m², at 24^th week it was 0.8 kg/m² and at 48th week it was 0.5kg/m2. 8% of subjects had an AE-intermittent diarrhea and no SAE was detected.

Conclusion: In real scenario, combination of tenegliptin 20mg with metformin 1000mg was associated with clinically significant reduction in HbA1c.